Protein binding, sister chromatid exchange and expression of oncogene proteins in patients treated with cisplatinum (cisDDP)-based chemotherapy

The aim of this pilot was to evaluate the feasibility of incorporating several complementary biologic markers into a molecular epidemiologic study of chemotherapy patients. Thirty-two cancer patients being treated with cis-DDP-based chemotherapy for the first time were enrolled in the study and dona...

Full description

Saved in:
Bibliographic Details
Published in:Archives of toxicology 1990-01, Vol.64 (5), p.401-406
Main Authors: PERERA, F, FISCHMAN, H. K, STOOPLER, M, HEMMINKI, K, BRANDT-RAUF, P, NIMAN, H. L, SMITH, S, TOPOROFF, E, O'DOWD, K, TANG, M. X, TSAI, W. Y
Format: Article
Language:English
Subjects:
Aged
Amino Acid Sequence
Biological and medical sciences
Blood Proteins - metabolism
Cisplatin - adverse effects
Cisplatin - therapeutic use
Drug toxicity and drugs side effects treatment
Gene Expression Regulation, Neoplastic - drug effects
Hemoglobins - metabolism
Humans
Medical sciences
Middle Aged
Miscellaneous (drug allergy, mutagens, teratogens...)
Molecular Sequence Data
Neoplasms - drug therapy
Oncogene Proteins - biosynthesis
Oncogene Proteins - blood
Oncogenes - drug effects
Pharmacology. Drug treatments
Protein Binding
Sister Chromatid Exchange - drug effects
Spectrophotometry, Ultraviolet
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this pilot was to evaluate the feasibility of incorporating several complementary biologic markers into a molecular epidemiologic study of chemotherapy patients. Thirty-two cancer patients being treated with cis-DDP-based chemotherapy for the first time were enrolled in the study and donated a baseline sample and at least one post-treatment sample of blood. Sister Chromatid Exchange (SCEs) and plasma protein and hemoglobin binding by cisDDP were significantly increased in samples drawn at various timepoints following treatment. The pattern of nine different oncogene protein products (including those of ras, fes, and myc) remained unchanged in sera of six patients followed over the course of their treatment. However, the levels of ras P21 product were significantly elevated above normal, control levels in all six cancer patients--both prior to and throughout the course of chemotherapy. These results suggest the usefulness of utilizing a battery of markers to evaluate biologic response to cisplatinum-based chemotherapy.
ISSN:0340-5761
1432-0738
DOI:10.1007/BF01973463